Clinical Trial Update: An Expanded Access Study to Assess Treprostinil Palmitil Inhalation Powder (TPIP) for Participants With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

View source ↗

Summary

An expanded access study evaluating Treprostinil Palmitil Inhalation Powder (TPIP) for patients with pulmonary arterial hypertension and pulmonary hypertension …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Arterial Hypertension
• Pulmonary Hypertension Associated with Interstitial Lung Disease

Drugs mentioned

• Treprostinil Palmitil Inhalation Powder (TPIP) (treprostinil palmitil inhalation powder)

Snippet

Sponsor: Insmed Incorporated | Conditions: Pulmonary Arterial Hypertension, Pulmonary Hypertension, Interstitial Lung Disease | Status: AVAILABLE